What service do you need? Contact Request

NCT06507436

The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

← Hub

Registry fields

Overall status: COMPLETED
Conditions: Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Study type: INTERVENTIONAL
Phase: PHASE3
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: Herombopag tablets, Herombopag placebo tablets
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)

Cached at: 2026-08-28 23:27:15

View on ClinicalTrials.gov

Brief summary

This study includes Part A and Part B. Part A is a dose-finding study for subjects with chronic liver disease-related thrombocytopenia scheduled for elective surgery. Part B is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy and safety of Herombopag compared to placebo in patients with chronic liver disease-related thrombocytopenia undergoing elective invasive surgery.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report